{"id":2338,"date":"2020-07-08T00:00:00","date_gmt":"2020-07-08T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2338"},"modified":"2020-07-08T00:00:00","modified_gmt":"2020-07-08T00:00:00","slug":"centogene-oglasza-proponowana-pierwotna-i-wtorna-oferte-publiczna-akcji-zwyklych","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"CENTOGENE og\u0142asza proponowan\u0105 pierwotn\u0105 i wt\u00f3rn\u0105 ofert\u0119 publiczn\u0105 akcji zwyk\u0142ych"},"content":{"rendered":"<p>CAMBRIDGE, Massachusetts, ROSTOCK, Niemcy i BERLIN, 7 lipca 2020 r. (Globe Newswire) \u2013 Centogene NV (Nasdaq: CNTG), sp\u00f3\u0142ka komercyjna specjalizuj\u0105ca si\u0119 w chorobach rzadkich, kt\u00f3ra przetwarza rzeczywiste dane kliniczne i genetyczne w u\u017cyteczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych, og\u0142osi\u0142a dzisiaj, \u017ce wraz z wybranymi akcjonariuszami sprzedaj\u0105cymi rozpocz\u0119\u0142a publiczn\u0105 ofert\u0119 gwarantowan\u0105 3\u00a0500\u00a0000 akcji zwyk\u0142ych Sp\u00f3\u0142ki, w tym 2\u00a0000\u00a0000 akcji zwyk\u0142ych oferowanych przez Sp\u00f3\u0142k\u0119 i 1\u00a0500\u00a0000 akcji zwyk\u0142ych oferowanych przez akcjonariuszy sprzedaj\u0105cych. Ponadto akcjonariusze sprzedaj\u0105cy przewiduj\u0105 udzielenie gwarantom 30-dniowej opcji zakupu do 525\u00a0000 dodatkowych akcji zwyk\u0142ych po cenie oferty publicznej, pomniejszonej o dyskonto i prowizje gwaranta emisji. Oferta podlega warunkom rynkowym i innym warunkom. Nie ma pewno\u015bci co do tego, czy i kiedy oferta zostanie zrealizowana, ani co do jej rzeczywistej wielko\u015bci lub warunk\u00f3w.<\/p>\n<p>Credit Suisse i SVB Leerink pe\u0142ni\u0105 funkcj\u0119 wsp\u00f3\u0142mened\u017cer\u00f3w ksi\u0119gi popytu w ramach proponowanej oferty, a Baird, BTIG i Kempen &amp; Co pe\u0142ni\u0105 funkcj\u0119 wsp\u00f3\u0142mened\u017cer\u00f3w.<\/p>\n<p>CENTOGENE zamierza przeznaczy\u0107 doch\u00f3d netto z oferty na badania i rozw\u00f3j, wspieraj\u0105c rozw\u00f3j lek\u00f3w sierocych za pomoc\u0105 swojej platformy informacyjnej opartej na wiedzy, a tak\u017ce na kapita\u0142 obrotowy i inne og\u00f3lne cele korporacyjne. Cz\u0119\u015b\u0107 dochodu netto mo\u017ce r\u00f3wnie\u017c zosta\u0107 przeznaczona na nabycie lub inwestycje w komplementarne przedsi\u0119biorstwa, aktywa lub technologie.<\/p>\n<p>Oferta jest realizowana wy\u0142\u0105cznie za po\u015brednictwem prospektu emisyjnego. Egzemplarze wst\u0119pnego prospektu emisyjnego dotycz\u0105cego oferty, o ile jest dost\u0119pny, mo\u017cna uzyska\u0107 bezp\u0142atnie, odwiedzaj\u0105c stron\u0119 internetow\u0105 EDGAR Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (\u201cSEC\u201d) pod adresem www.sec.gov. Alternatywnie, egzemplarze wst\u0119pnego prospektu emisyjnego, o ile s\u0105 dost\u0119pne, mo\u017cna uzyska\u0107 w Credit Suisse Securities (USA) LLC, z dopiskiem: Dzia\u0142 Prospekt\u00f3w, 6933 Louis Stephens Drive, Morrisville, NC 27560, telefonicznie pod numerem (800) 221-1037 lub e-mailem na adres usa.prospectus@credit-suisse.com; lub w SVB Leerink LLC, z dopiskiem: Dzia\u0142 Syndykat\u00f3w, One Federal Street, 37th Floor, Boston, MA 02110, telefonicznie pod numerem (800) 808-7525, wew. 6218 lub e-mailem na adres syndicate@svbleerink.com .<\/p>\n<p>O\u015bwiadczenie rejestracyjne dotycz\u0105ce oferty zosta\u0142o z\u0142o\u017cone w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC), ale nie wesz\u0142o jeszcze w \u017cycie. Papiery warto\u015bciowe nie mog\u0105 zosta\u0107 sprzedane ani oferty kupna nie mog\u0105 zosta\u0107 przyj\u0119te przed wej\u015bciem w \u017cycie o\u015bwiadczenia rejestracyjnego.<\/p>\n<p>Niniejszy komunikat prasowy nie stanowi oferty sprzeda\u017cy ani zach\u0119ty do z\u0142o\u017cenia oferty kupna tych papier\u00f3w warto\u015bciowych. Nie b\u0119dzie r\u00f3wnie\u017c mia\u0142a miejsca sprzeda\u017c tych papier\u00f3w warto\u015bciowych w \u017cadnym stanie ani jurysdykcji, w kt\u00f3rych taka oferta, zach\u0119ta lub sprzeda\u017c by\u0142aby niezgodna z prawem przed rejestracj\u0105 lub kwalifikacj\u0105 zgodnie z przepisami prawa papier\u00f3w warto\u015bciowych obowi\u0105zuj\u0105cymi w takim stanie lub jurysdykcji.<\/p>\n<h2 class=\"h3\">O firmie CENTOGENE<strong> <\/strong><\/h2>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne i genetyczne w praktyczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych, wykorzystuj\u0105c nasz\u0105 rozleg\u0142\u0105 wiedz\u0119 na temat chor\u00f3b rzadkich, w tym dane epidemiologiczne i kliniczne, a tak\u017ce innowacyjne biomarkery. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 chor\u00f3b rzadkich opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, obejmuj\u0105cym oko\u0142o 3 miliardy wa\u017conych punkt\u00f3w danych od ponad 530 000 pacjent\u00f3w z ponad 120 kraj\u00f3w (stan na 31 marca 2020 r.).<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi tych pacjent\u00f3w. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma, kt\u00f3ra kompleksowo analizuje dane wielopoziomowe w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych, co mo\u017ce pom\u00f3c w identyfikacji pacjent\u00f3w i usprawni\u0107 wprowadzanie lek\u00f3w sierocych na rynek przez naszych partner\u00f3w farmaceutycznych. Na dzie\u0144 31 marca 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z 39 partnerami farmaceutycznymi, obejmuj\u0105cymi ponad 45 r\u00f3\u017cnych chor\u00f3b rzadkich.<\/p>\n<h5>Kontakt dla medi\u00f3w<strong> <\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Dyrektor ds. strategii i relacji inwestorskich<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Napisz e-mail\">investor.relations@centogene.com<\/a><\/p>\n<p>Doradztwo FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Napisz e-mail\">bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2338","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-oglasza-proponowana-pierwotna-i-wtorna-oferte-publiczna-akcji-zwyklych\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-oglasza-proponowana-pierwotna-i-wtorna-oferte-publiczna-akcji-zwyklych\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-08T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":643,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE og\u0142asza proponowan\u0105 pierwotn\u0105 i wt\u00f3rn\u0105 ofert\u0119 publiczn\u0105 akcji zwyk\u0142ych | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-oglasza-proponowana-pierwotna-i-wtorna-oferte-publiczna-akcji-zwyklych\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-oglasza-proponowana-pierwotna-i-wtorna-oferte-publiczna-akcji-zwyklych\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-08T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"3 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-08T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":643,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE og\u0142asza proponowan\u0105 pierwotn\u0105 i wt\u00f3rn\u0105 ofert\u0119 publiczn\u0105 akcji zwyk\u0142ych | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-08T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Wyznaczanie kierunku medycyny precyzyjnej","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2338"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}